

HIV AND STDS IN SAN FRANCISCO





Health Commission Meeting Sept 17, 2019




Outline of Presentations

- I. Highlights from the Annual HIV Surveillance Report
- 2. Progress in HIV Getting to Zero
- 3. Progress in addressing STDs




HIV Diagnoses, Deaths, and Prevalence, 2006-2018




- Overall 94% of PLWH are aware of their HIV status
- New diagnoses decreased 13% between 2017-2018
- No children were diagnosed since 2005
- Nearly 16,000 living HIV cases
- Aging epidemic: 67% of PLWH > 50 years; 30% > 60 years

Continuum of HIV Care among Persons Diagnosed with HIV



Faster Time to Care Indicators






POPULATION HEALTH DIVISION

Underlying Causes of Death among Persons with HIV

Non-AIDS cancer			Year of Death		
Number (%) HIV S91(51.7) 391(41.2) 366(38.0) HIV-reconstruction S91(51.7) 391(41.2) 366(38.0) HIV-reconstruction S91(51.7) 391(41.2) 366(38.0) HIV-reconstruction S91(51.7) 391(41.2) 366(38.0) HIV-reconstruction S91(51.7) 391(41.2) 366(38.0) S91(51.7) 391(41.2) 31(3.3) 34(3.5) declinates S91(51.2)		2006-2009	2010-2013	2014-2017	
HIV S91(51.7) 391(41.2) 366(38.0) HIV-reconstruction 120(10.8) 136(14.3) 144(15.0) Cause 123(10.8) 136(14.3) 34(3.5) declir 124(1.5) Cause 124(1.5) Cause 124(1.5) Cause 124(1.6) Cause 124(1.6) Cause 124(1.6) Cause 124(1.6) Cause 124(1.8) Cause 124(10.6) Cause 124(1.8) Cause C	_	N=1,143	N=949	N=962	
Non-AIDS cancer 2nd leading cause 123(10.8) 136(14.3) 144(15.0) cause Lung cancer of death 47(4.1) 31(3.3) 34(3.5) declir Liver cancer • African 18(1.6) 22(2.3) 14(1.5) • Wo Anal cancer • African 5(0.4) 9(0.9) 12(1.2) • Lat Colon cancer 4(0.3) 8(0.8) 6(0.6) 6(0.6) Acacidents 4(0.3) 4(0.4) 3(0.3) Acacidents 12(10.6) 112(11.8) 120(12.5) 3rd leading cause Acacidents 12(10.6) 12(1.2) • Lat • Wo • Lat			Number (%)		
Lung cancer of death 47(4.1) 31(3.3) 34(3.5) declir Liver cancer • African 18(1.6) 22(2.3) 14(1.5) • Wo Anal cancer 5(0.4) 9(0.9) 12(1.2) • Lat Colon cancer 9(0.8) 5(0.5) 6(0.6) • Lat Pancreatic cancer 4(0.3) 8(0.8) 6(0.6) • Lat Rectal cancer 4(0.3) 4(0.4) 3(0.3) • Lat Hodgkins lymphoma 2(0.2) 2(0.2) 1(0.1) • Leukemia 0(0.0) 6(0.6) 1(0.1) Leukemia 0(0.0) 6(0.6) 1(0.1) 3rd let death Drug overdose 93(8.1) 97(10.2) 100(10.4) death Heart disease 87(7.6) 83(8.7) 103(10.7) • PW Coronary heart disease 45(3.9) 42(4.4) 49(5.1) • PW Cardiomyopathy 6(0.5) 4(0.4) 7(0.7) Suicide 50(4.4) 37(3.9) 32(3.3) Liver disease 11(1.0) 6(0.6) 15(1.6) Liver disease	HIV	591(51.7)	391(41.2)	366(38.0)	HIV-related
Lung cancer of death 47(4.1) 31(3.3) 34(3.5) declir Liver cancer • African 18(1.6) 22(2.3) 14(1.5) • Wo Anal cancer 5(0.4) 9(0.9) 12(1.2) • Lat Colon cancer 4(0.3) 8(0.8) 6(0.6) Pancreatic cancer 4(0.3) 4(0.4) 3(0.3) Hodgkins lymphoma 2(0.2) 2(0.2) 1(0.1) Leukemia 0(0.0) 6(0.6) 1(0.1) Accidents 121(10.6) 112(11.8) 120(12.5) Drug overdose 93(8.1) 97(10.2) 100(10.4) Heart disease 87(7.6) 83(8.7) 103(10.7) • PW Coronary heart disease 45(3.9) 42(4.4) 49(5.1) • MS Cardiomyopathy 6(0.5) 4(0.4) 7(0.7) • MS Suicide 50(4.4) 37(3.9) 32(3.3) • Liver disease 11(1.0) 6(0.6) 15(1.6) • MS Liver disease 11(1.0) 6(0.6) 15(1.6) <td>Non-AIDS cancer 2nd leading cause</td> <td>123(10.8)</td> <td>136(14.3)</td> <td>144(15.0)</td> <td>causes of death</td>	Non-AIDS cancer 2 nd leading cause	123(10.8)	136(14.3)	144(15.0)	causes of death
Liver cancer Anal cancer American 20%		47(4.1)	31(3.3)	34(3.5)	declining
Anal cancer Colon cancer Colon cancer Colon cancer Pancreatic cancer Pancreatic cancer Rectal cancer Phodgkins lymphoma Paccidents Prug overdose Part disease Cardiomyopathy Cardiomyopathy Cardiomyopathy Cardiomic disease Pancreatic cancer Pancrea	Liver concer	18(1.6)	22(2.3)	14(1.5)	• Women 42%
Colon cancer 9 (0.8) 5 (0.5) 6 (0.6) Pancreatic cancer 4 (0.3) 8 (0.8) 6 (0.6) Rectal cancer 4 (0.3) 4 (0.4) 3 (0.3) Hodgkins lymphoma 2 (0.2) 2 (0.2) 1 (0.1) Leukemia 0 (0.0) 6 (0.6) 1 (0.1) Accidents 121 (10.6) 112 (11.8) 120 (12.5) Drug overdose 93 (8.1) 97 (10.2) 100 (10.4) Heart disease 87 (7.6) 83 (8.7) 103 (10.7) Coronary heart disease 45 (3.9) 42 (4.4) 49 (5.1) Cardiomyopathy 6 (0.5) 4 (0.4) 7 (0.7) Suicide 50 (4.4) 37 (3.9) 32 (3.3) Liver disease 27 (2.4) 21 (2.2) 25 (2.6) Alcoholic liver disease 11 (1.0) 6 (0.6) 15 (1.6) Liver cirrhosis 14 (1.2) 14 (1.5) 7 (0.7) Chronic obstructive pulmonary disease 25 (2.2) 17 (1.8) 23 (2.4) Assault 8 (0.7) 9 (0.9) 14 (1.5) Cerebrovascular disease 8 (0.7) 10 (1.1) 13 (1.4) Diabetes	Anal cancer	5(0.4)	9(0.9)	12(1.2)	• Latinx 46%
Rectal cancer 4(0.3) 4(0.4) 3(0.3) Hodgkins lymphoma 2(0.2) 2(0.2) 1(0.1) Leukemia 0(0.0) 6(0.6) 1(0.1) Accidents 121(10.6) 112(11.8) 120(12.5) Drug overdose 93(8.1) 97(10.2) 100(10.4) death Heart disease 87(7.6) 83(8.7) 103(10.7) PM Coronary heart disease 45(3.9) 42(4.4) 49(5.1) MS Cardiomyopathy 6(0.5) 4(0.4) 7(0.7) Suicide 50(4.4) 37(3.9) 32(3.3) Liver disease 27(2.4) 21(2.2) 25(2.6) Alcoholic liver disease 11(1.0) 6(0.6) 15(1.6) Liver cirrhosis 14(1.2) 14(1.5) 7(0.7) Chronic obstructive pulmonary disease 25(2.2) 17(1.8) 23(2.4) Assault 8(0.7) 9(0.9) 14(1.5) Cerebrovascular disease 8(0.7) 10(1.1) 13(1.4) Diabetes 1(0.1) 11(1.2) 11(1.1)	Colon cancer	9(0.8)	5(0.5)	6(0.6)	Lacilla 40%
Hodgkins lymphoma 2 (0.2) 2 (0.2) 1 (0.1) Leukemia 0 (0.0) 6 (0.6) 1 (0.1) Accidents 121 (10.6) 112 (11.8) 120 (12.5) Drug overdose 93 (8.1) 97 (10.2) 100 (10.4) Heart disease 87 (7.6) 83 (8.7) 103 (10.7) Coronary heart disease 45 (3.9) 42 (4.4) 49 (5.1) Cardiomyopathy 6 (0.5) 4 (0.4) 7 (0.7) Suicide 50 (4.4) 37 (3.9) 32 (3.3) Liver disease 27 (2.4) 21 (2.2) 25 (2.6) Alcoholic liver disease 11 (1.0) 6 (0.6) 15 (1.6) Liver cirrhosis 14 (1.2) 14 (1.5) 7 (0.7) Chronic obstructive pulmonary disease 25 (2.2) 17 (1.8) 23 (2.4) Assault 8 (0.7) 9 (0.9) 14 (1.5) Cerebrovascular disease 8 (0.7) 10 (1.1) 13 (1.4) Diabetes 1 (0.1) 11 (1.2) 11 (1.1)	Pancreatic cancer	4(0.3)	8(0.8)	6(0.6)	
Leukemia 0 (0.0) 6 (0.6) 1 (0.1) Accidents 121 (10.6) 112 (11.8) 120 (12.5) Drug overdose 93 (8.1) 97 (10.2) 100 (10.4) death Heart disease 87 (7.6) 83 (8.7) 103 (10.7) • PW Coronary heart disease 45 (3.9) 42 (4.4) 49 (5.1) • PW Cardiomyopathy 6 (0.5) 4 (0.4) 7 (0.7) Suicide 50 (4.4) 37 (3.9) 32 (3.3) Liver disease 27 (2.4) 21 (2.2) 25 (2.6) Alcoholic liver disease 11 (1.0) 6 (0.6) 15 (1.6) Liver cirrhosis 14 (1.2) 14 (1.5) 7 (0.7) Chronic obstructive pulmonary disease 25 (2.2) 17 (1.8) 23 (2.4) Assault 8 (0.7) 9 (0.9) 14 (1.5) Cerebrovascular disease 8 (0.7) 10 (1.1) 13 (1.4) Diabetes 1 (0.1) 11 (1.1) 11 (1.1)	Rectal cancer	4(0.3)	4(0.4)	3(0.3)	
Accidents 121(10.6) 112(11.8) 120(12.5) 3rd lead Drug overdose 93(8.1) 97(10.2) 100(10.4) death Heart disease 87(7.6) 83(8.7) 103(10.7) • PW Coronary heart disease 45(3.9) 42(4.4) 49(5.1) • PW Cardiomyopathy 6(0.5) 4(0.4) 7(0.7) Suicide 50(4.4) 37(3.9) 32(3.3) Liver disease 27(2.4) 21(2.2) 25(2.6) Alcoholic liver disease 11(1.0) 6(0.6) 15(1.6) Liver cirrhosis 14(1.2) 14(1.5) 7(0.7) Chronic obstructive pulmonary disease 25(2.2) 17(1.8) 23(2.4) Assault 8(0.7) 9(0.9) 14(1.5) Cerebrovascular disease 8(0.7) 10(1.1) 13(1.4) Diabetes 1(0.1) 11(1.2) 11(1.1)	Hodgkins lymphoma	2(0.2)	2(0.2)	1(0.1)	
Drug overdose 93 (8.1) 97 (10.2) 100 (10.4) death Heart disease 87 (7.6) 83 (8.7) 103 (10.7) • PW Coronary heart disease 45 (3.9) 42 (4.4) 49 (5.1) • MS Cardiomyopathy 6 (0.5) 4 (0.4) 7 (0.7) Suicide 50 (4.4) 37 (3.9) 32 (3.3) Liver disease 27 (2.4) 21 (2.2) 25 (2.6) Alcoholic liver disease 11 (1.0) 6 (0.6) 15 (1.6) Liver cirrhosis 14 (1.2) 14 (1.5) 7 (0.7) Chronic obstructive pulmonary disease 25 (2.2) 17 (1.8) 23 (2.4) Assault 8 (0.7) 9 (0.9) 14 (1.5) Cerebrovascular disease 8 (0.7) 10 (1.1) 13 (1.4) Diabetes 1 (0.1) 11 (1.2) 11 (1.1)	Leukemia	0(0.0)	6(0.6)	1(0.1)	
Heart disease 87(7.6) 83(8.7) 103(10.7) Coronary heart disease 45(3.9) 42(4.4) 49(5.1) Cardiomyopathy 6(0.5) 4(0.4) 7(0.7) Suicide 50(4.4) 37(3.9) 32(3.3) Liver disease 27(2.4) 21(2.2) 25(2.6) Alcoholic liver disease 11(1.0) 6(0.6) 15(1.6) Liver cirrhosis 14(1.2) 14(1.5) 7(0.7) Chronic obstructive pulmonary disease 25(2.2) 17(1.8) 23(2.4) Assault 8(0.7) 9(0.9) 14(1.5) Cerebrovascular disease 8(0.7) 10(1.1) 13(1.4) Diabetes 1(0.1) 11(1.2) 11(1.1)	Accidents	121(10.6)	112(11.8)	120(12.5)	3 rd leading cause of
Coronary heart disease 45(3.9) 42(4.4) 49(5.1) Cardiomyopathy 6(0.5) 4(0.4) 7(0.7) Suicide 50(4.4) 37(3.9) 32(3.3) Liver disease 27(2.4) 21(2.2) 25(2.6) Alcoholic liver disease 11(1.0) 6(0.6) 15(1.6) Liver cirrhosis 14(1.2) 14(1.5) 7(0.7) Chronic obstructive pulmonary disease 25(2.2) 17(1.8) 23(2.4) Assault 8(0.7) 9(0.9) 14(1.5) Cerebrovascular disease 8(0.7) 10(1.1) 13(1.4) Diabetes 1(0.1) 11(1.2) 11(1.1)	Drug overdose	93(8.1)	97(10.2)	100(10.4)	death
Cardiomyopathy 6(0.5) 4(0.4) 7(0.7) Suicide 50(4.4) 37(3.9) 32(3.3) Liver disease 27(2.4) 21(2.2) 25(2.6) Alcoholic liver disease 11(1.0) 6(0.6) 15(1.6) Liver cirrhosis 14(1.2) 14(1.5) 7(0.7) Chronic obstructive pulmonary disease 25(2.2) 17(1.8) 23(2.4) Assault 8(0.7) 9(0.9) 14(1.5) Cerebrovascular disease 8(0.7) 10(1.1) 13(1.4) Diabetes 1(0.1) 11(1.2) 11(1.1)	Heart disease	87 (7.6)	83 (8.7)	103(10.7)	• PWID 16%
Cardiomyopathy 6(0.5) 4(0.4) 7(0.7) Suicide 50(4.4) 37(3.9) 32(3.3) Liver disease 27(2.4) 21(2.2) 25(2.6) Alcoholic liver disease 11(1.0) 6(0.6) 15(1.6) Liver cirrhosis 14(1.2) 14(1.5) 7(0.7) Chronic obstructive pulmonary disease 25(2.2) 17(1.8) 23(2.4) Assault 8(0.7) 9(0.9) 14(1.5) Cerebrovascular disease 8(0.7) 10(1.1) 13(1.4) Diabetes 1(0.1) 11(1.2) 11(1.1)	Coronary heart disease	45(3.9)	42 (4.4)	49 (5.1)	 MSM PWID 21%
Liver disease 27(2.4) 21(2.2) 25(2.6) Alcoholic liver disease 11(1.0) 6(0.6) 15(1.6) Liver cirrhosis 14(1.2) 14(1.5) 7(0.7) Chronic obstructive pulmonary disease 25(2.2) 17(1.8) 23(2.4) Assault 8(0.7) 9(0.9) 14(1.5) Cerebrovascular disease 8(0.7) 10(1.1) 13(1.4) Diabetes 1(0.1) 11(1.2) 11(1.1)	Cardiomyopathy	6(0.5)	4(0.4)	7(0.7)	110111 1112 2170
Alcoholic liver disease 11(1.0) 6(0.6) 15(1.6) Liver cirrhosis 14(1.2) 14(1.5) 7(0.7) Chronic obstructive pulmonary disease 25(2.2) 17(1.8) 23(2.4) Assault 8(0.7) 9(0.9) 14(1.5) Cerebrovascular disease 8(0.7) 10(1.1) 13(1.4) Diabetes 1(0.1) 11(1.2) 11(1.1)	Suicide	50(4.4)	37(3.9)	32(3.3)	
Liver cirrhosis $14(1.2)$ $14(1.5)$ $7(0.7)$ Chronic obstructive pulmonary disease $25(2.2)$ $17(1.8)$ $23(2.4)$ Assault $8(0.7)$ $9(0.9)$ $14(1.5)$ Cerebrovascular disease $8(0.7)$ $10(1.1)$ $13(1.4)$ Diabetes $1(0.1)$ $11(1.2)$ $11(1.1)$	Liver disease	27(2.4)	21(2.2)	25(2.6)	
Chronic obstructive pulmonary disease 25(2.2) 17(1.8) 23(2.4) Assault 8(0.7) 9(0.9) 14(1.5) Cerebrovascular disease 8(0.7) 10(1.1) 13(1.4) Diabetes 1(0.1) 11(1.2) 11(1.1)	Alcoholic liver disease	11(1.0)	6(0.6)	15 (1.6)	
Assault 8(0.7) 9(0.9) 14(1.5) Cerebrovascular disease 8(0.7) 10(1.1) 13(1.4) Diabetes 1(0.1) 11(1.2) 11(1.1)	Liver cirrhosis	14(1.2)	14(1.5)	7(0.7)	
Cerebrovascular disease 8(0.7) 10(1.1) 13(1.4) Diabetes 1(0.1) 11(1.2) 11(1.1)	Chronic obstructive pulmonary disease	25(2.2)	17(1.8)	23(2.4)	
Diabetes 1(0.1) 11(1.2) 11(1.1)	Assault	8(0.7)	9(0.9)	14(1.5)	
	Cerebrovascular disease	8(0.7)	10(1.1)	13(1.4)	
Montal disorders due to substance use 22/10 \ 10/11\ \ 11/11\	Diabetes	1(0.1)	11(1.2)	11(1.1)	
wiental disorders due to substance use 22(1.9) 10(1.1) 11(1.1)	Mental disorders due to substance use	22(1.9)	10(1.1)	11(1.1)	




Number of Persons Diagnosed with HIV by Race/Ethnicity









Number of New Diagnoses by Demographic Characteristics




Annual Rates of Men Diagnosed with HIV by Race/Ethnicity




Annual Rates of Women Diagnosed with HIV by Race/Ethnicity




Health Disparities Survival After AIDS, 2012-2016



Disparities in Viral Suppression



Number and Percent of Homeless Persons Diagnosed with HIV





Characteristics of Homeless Persons or SRO Residents with HIV

Homeless at Diagnosis

			Hom	eless	All Diagnoses				
		Total	422		3,488				
	er	Men	328	(78)	3,113	(89)			
	Gender	Women	56	(13)	260	(7)			
	Ğ	Trans Women	38	(9)	115	(3)			
	ţ.	White	173	(41)	1,558	(45)			
	Race/Ethnicity	African American	104	(25)	477	(14)			
	Æ.	Latinx	102	(24)	901	(26)			
	/eoe	Asian/Pacific Islander	10	(2)	378	(11)			
	<u>~~</u>	Other/Unknown	33	(8)	174	(5)			
	ory	MSM	127	(30)	2,408	(69)			
	teg	TWSM	25	(6)	78	(2)			
	Ca	PWID	108	(26)	249	(7)			
	sior	MSM-PWID	106	(25)	417	(12)			
	ansmis	TWSM-PWID	13	(3)	35	(1)			
		Heterosexual	32	(8)	208	(6)			
	Ĕ	Other/Unidentified	11	(3)	93	(3)			
	. <u>is</u>	13 – 17	1	(<1)	12	(<1)			
	sou.	18 - 24	67	(16)	448	(13)			
	at Diagı (Years)	25 - 29	82	(19)	614	(18)			
	Age at Diagnosis (Years)	30 - 39	117	(28)	1,049	(30)			
	98	40 - 49	89	(21)	865	(25)			
	4	50+	66	(16)	500	(14)			

Homeless/SRO in 2018

		Home	eless/SRO	All PLWH		
	Total	601		7,849		
ē	Men	485	(81)	7,142	(91)	
Gender	Women	70	(12)	509	(6)	
<u> </u>	Trans women	46	(8)	198	(3)	
<u>:</u>	White	261	(43)	4,516	(58)	
Race/Ethnicity	African American	127	(21)	970	(12)	
Ē.	Latinx	152	(25)	1,548	(20)	
ace/	Asian/Pacific Islander	31	(5)	505	(6)	
<u>~~~~</u>	Other/Unknown	30	(5)	310	(4)	
<u> </u>	MSM	242	(40)	5,723	(73)	
tego	TWSM	25	(4)	117	(1)	
Transmission category	PWID	110	(18)	456	(6)	
sior	MSM-PWID	165	(27)	1,055	(13)	
mis	TWSM-PWID	20	(3)	74	(1)	
ansi	Heterosexual	30	(5)	309	(4)	
Ĕ	Other/Unidentified	9	(1)	115	(1)	
~	13-24	7	(1)	69	(1)	
s 018	25-29	34	(6)	224	(3)	
rear 1/2	30-39	134	(22)	899	(11)	
Age in years (as of 12/31/2018)	40-49	130	(22)	1,522	(19)	
Age of 1	50-59	192	(32)	2,781	(35)	
as	60-69	87	(14)	1,830	(23)	
	70+	17	(3)	524	(7)	

Getting to Zero San Francisco



Collective Impact

GTZ is a multi-sector consortium that operates under principles of collective impact:

"Commitment of groups from different sectors to a common agenda to solve a specific problem."

Common Agenda

Keeps all parties moving towards the same goal

Common Progress Measures

Measures that get to the TRUE outcome

Mutually Reinforcing Activities

Each expertise is leveraged as part of the overall


Communications


This allows a culture of collaboration

Backbone Organization

Takes on the role of managing collaboration

Getting to Zero: Built on Collective Impact Free Standing Organization






Strategic priorities for San Francisco Getting to Zero Consortium

City-wide coordinated PrEP program Rapid ART start with treatment hubs

Linkageengagementretention in care

Reducing HIV stigma

Adolescent & Young Adult



Committee for each initiative is developing action plan, metrics and milestones.

Drug user health

Mental health/ Substance use/Housing as HIV prevention

Linkage to care and partner services (LINCS)

Treatment as prevention

Primary care HIV screening

Syringe access


Health ed/risk reduction

STD testing & treatment

Prevention with positives

HIV testing

SF PrEP Cascade, MSM and Trans women
















New strategies in PrEP delivery in development

- Pairing PrEP navigators with online tools to help providers with panel management
- Integrating PrEP support app components with online pharmacy delivery service
- Offering "on demand" PrEP with app support tools




"RAPID": First-in-kind US program of treatment on diagnosis

Same day linkage and PrEP start leads to:

- Reduces HIV illness and death
- Reduces transmission
- Empowers patient for disclosure

Elements:

- Transportation to hub
- Meet with MD, social worker
- Baseline labs
- Counseling
- Medical/psychosocial assessment and linkage
- ART (starter pack)




Retention and Re-engagement: The Toughest Step in the Care Cascade

- Expanded "LINCS": Linkage, Integration, Navigation, and Comprehensive Services for PLWH not in care
- Scale-up of intensive case management
- Food security
- Employment services
- Front-line organizing group
- Cell phone charging stations




Proportion Virally Suppressed

Overall vs. LINCS




Contribution to deaths among people with HIV

% of deaths in which these factors contributed to death




Net Migration in 2014 (SF)




Conclusions

- Collective impact has been a fruitful mechanism for working together
- Great progress is being made but disparities remain
 - Must dig deeper into addressing poor outcomes for African Americans and Latinx
 - More programs for PWID including safe injection sites
- Integrating interventions for HIV with STI/HCV prevention and treatment
- Need Bay Area-wide efforts
- Next stage of programs must focus on homelessness, substance use, mental health
 - We will get to zero, but not without housing!



"Health Access Points"

Goal: Reduce disparities by addressing vulnerabilities through focused community investment.





"Health Access Point" Attributes

- Stigma-free, welcoming, culturally appropriate environment
- "Status neutral"
- Population-specific
- Baseline standard of care, for all populations
- Low barrier access:
 - Mobile and field-based work
 - Consistent services offered at the same time, same place, same teams
 - Frequent recurring contacts

- Interdisciplinary
- Clinical and community-based elements
- Single location, multi-location network, or other approach
- Shared data, risk assessment, & care plans

Essential for sustainability:

- Accountability
- Workforce development
- Organizational capacity-building



Ending
the
HIV
Epidemic

HHS Has Launched A New Initiative to End the HIV Epidemic in America

GOAL:

75%
reduction
in new HIV
infections
in 5 years
and at least
90%
reduction
in 10 years.





Diagnose all people with HIV as early as possible after infection.

Treat the infection rapidly and effectively to achieve sustained viral suppression.





Prevent people at risk for HIV using potent and proven prevention interventions, including PrEP, a medication that can prevent HIV infections.

Respond rapidly to detect and respond to growing HIV clusters and prevent new HIV infections.





HIV Workforce will establish local teams committed to the success of the Initiative in each jurisdiction.





STD Prevention in San Francisco




Increasing Syphilis in Women and Congenital Syphilis





- Cases of mother-to-child transmission of syphilis (Congenital Syphilis) are increasing in the United States and in California
- Congenital syphilis can lead to stillbirth and neonatal death
- Treating a pregnant women with injectable penicillin cures her syphilis infection, and prevents transmission to her baby
- Trends of increasing syphilis cases in women are often followed by increases in cases of congenital syphilis
- Nationally and in San Francisco, congenital syphilis has been associated with methamphetamine use, homelessness and lack of prenatal care

Total Female Syphilis Cases, San Francisco 2013-2019



Confirmation of Pregnancy Status and CS Prevention Efforts





Pregnant Female Syphilis Cases in 2018 and through Q2 2019

	Ì	Ì	· ·	ì	ì	*	*	\$	ì	· ·
#	1	2	3	4	5	6	7	8	9	10
Experiencing Homelessness	✓		✓		✓	✓	✓	✓	✓	✓
Methamphetamine Use	✓				✓		✓		✓	✓
Pregnancy Outcome										
Baby born without congenital syphilis (7)	✓	✓	✓	✓	✓	✓	✓			
Mother treated, Still Pregnant (1)								✓		
Congenital Syphilis Case (2)									✓	✓

SFDPH Response to Increasing Syphilis among Women





Health Alert: Rising Rates of Syphilis Among Pregnant Women

May 22, 2019

Situational Update

In 2018 compared to 2017, there was an 88% increase in San Francisco of reported syphilis cases among women (from 64 to 120 total cases), the majority of which were among women of childbearing age. Approximately 30% of female syphilis cases reported experiencing homelessness, 35% reported methamphetamine use and 13% were diagnosed in emergency departments or urgent care settings.

Given rising rates of syphilis in women in San Francisco and rising rates of congenital syphilis across California, we are now recommending that all pregnant women be tested for syphilis at least twice during pregnancy.

Actions Requested of Clinicians

1. For all pregnant women, test for syphilis at least twice during pregnancy: 1) at the first clinical encounter (ideally during the first trimester) and 2) during third trimester (ideally between 28-32 weeks gestation). Women with risk factors for syphilis should be tested a third time at delivery. Infants should not be discharged from the hospital unless the mother has been tested for syphilis at least once during pregnancy.

- 5/22/19 provider Health Alert: increase frequency of routine blood screening for syphilis in all pregnant women to 1st and 3rd trimester.
- Women with syphilis, and their sex partners, are highest priority for the City Clinic disease investigation specialists (LINCS) who ensure treatment and prevention.
- On 6/3/19, the SFDPH Incident Command System (ICS) was activated to prevent congenital syphilis in San Francisco




SFDPH Response to Increasing Syphilis among Women

Activation Period 1 (6/3-9/3) key accomplishments:

- New partnership: City Clinic LINCS and MCAH public health nurses
- New rapid syphilis testing in Jail Health Services and Street Medicine
- Training and updates with community partner agencies
- Multidisciplinary Case Conference on 7/17/19 to review public health and clinical missed opportunities in CS cases
- PHD ARCHES and DPH IT collaboration to measure syphilis screening in ZSFG Emergency Department and Urgent Care

Continued 12 week activation periods planned through Spring 2020





PHD STD Strategic Framework Process

- Feb-June 2019, consultants conducted key informant interviews and facilitated seven meetings of internal and external stakeholders.
- Key theme was working across PHD Branches effectively
- Final Documentation and Next Steps are in process

Vision

A San Francisco where all people have safe, healthy sexual lives.

Mission

To provide information, services, and policies that prevent STDs and HIV, promote sexual and reproductive health, and enable all people in San Francisco to have safe, healthy sexual lives.

sfcityclinic.org

launched 8/22/19

GET MY RESULTS »



SERVICES


FOR PATIENTS

FOR PROVIDERS

ABOUT SFCC

CONTACT

1



Our Services



Walk-In Hours

Mon, Wed, Fri 8 a.m. – 4 p.m.


Tues 1 nm = 6 nm (1 - 3 nm symptoms only)

Faster Gonorrhea and Chlamydia Treatment for Patients and their Partners

- Rapid molecular testing for Chlamydia and Gonorrhea at City Clinic
- Collaboration between City Clinic and Public Health Lab
- Results in 90 minutes
- Began May 2018
- Goal is to more quickly treat the patient, for their health and to prevent sexual transmission to partners



Time to Treatment of Gonorrhea and Chlamydia: Pre vs. Post Implementation of the Rapid Test at City Clinic




Rapid Chlamydia and Gonorrhea Testing: Jail Health Services


Traditional lab based testing does not return results in time to treat many patients who may be released after screening

Added new moderate complexity lab and same rapid GC/CT Testing at the Jail in March 2019

Still in pilot phase



Rapid Testing in the Jail Decreases the Proportion of Patients with GC or CT who leave without Treatment



SLAY Council Goal:

 To develop and present recommendations to SFDPH for sexual health promotion and prevention strategies for maximum impact in the Southeastern communities of SF, created by Black women, for Black women.



Messages For Youth

- Respect Your Body
- STDs Can Happen To Anyone
- Sexual Health Is More Than Sex
- Communication Is Key
- Speak Your Truth





SLAY Recommendations for Connecting with Black/African American Young Women

MEET THEM WHERE THEY CONTINUOUSLY CHOOSE TO

ENGAGE

- Use language they can understand
- Social media and an informative website
- Hone in on target neighborhoods and communities
- Gain analytics on what worked, what reached them, and what needs improvement

INSTAGRAM

- Establish a community
- ❖ Posts, polls, quizzes, questions, and *Instagram Stories*
- Instagram Live as a safe space to ask questions and have realistic conversations with their peers

WEBSITE

- Use terms they can understand
- Platform to find more programs and resources
- One-stop place for in-depth sexual health information





THANK YOU!





Ling Hsu
Susan Buchbinder
Tracey Packer
Susan Philip
Jacqueline McCright

Design by Mehroz Baig v. 2017-4-14

